AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1903019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7028082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5% combined with guanethedine 1%
Number of subjects: 0
Study 7028082 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline 1%
Number of subjects: 0
Study 31669859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal foot flap for thumb reconstruction
Number of subjects: 104
Study 31669859 — intervention group
Group type: COMPARATOR
Intervention: Abdominal pedicled flap for thumb reconstruction
Number of subjects: 104
Study 31120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerial ultra-low volume (AULV) applications of chlorpyrifos insecticide
Number of subjects: 16
Study 31120502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AULV application)
Number of subjects: 16
Study 28511548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0
Study 28511548 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 25602908 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance notification letter (B)
Number of subjects: 39198
Study 25602908 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance notification letter followed by standard invitation (C)
Number of subjects: 39198
Study 25602908 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter (A)
Number of subjects: 39198
Study 25602908 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance notification letter (C)
Number of subjects: 39198
Study 24016559 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 141
Study 24016559 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine and hormone
Number of subjects: 141
Study 24016559 — intervention group
Group type: COMPARATOR
Intervention: Ginaton
Number of subjects: 141
Study 24016559 — intervention group
Group type: COMPARATOR
Intervention: Ginaton and hormone
Number of subjects: 141
Study 21477136 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirators (fit tested)
Number of subjects: 1441
Study 21477136 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirators (non-fit tested)
Number of subjects: 1441
Study 21477136 — intervention group
Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 1441
Study 21477136 — intervention group
Group type: COMPARATOR
Intervention: Convenience no-mask group
Number of subjects: 1441
Study 21477136 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 masks and hospital level
Number of subjects: 1441
Study 21477136 — intervention group
Group type: COMPARATOR
Intervention: Medical masks, vaccination, handwashing, high-risk procedures
Number of subjects: 1441
Study 19141586 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg)
Number of subjects: 31
Study 19141586 — intervention group
Group type: EXPERIMENTAL
Intervention: RU38486 (400 mg)
Number of subjects: 31
Study 19141586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spironolactone (200 mg) + RU38486 (400 mg)
Number of subjects: 31
Study 19141586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17729000 — intervention group
Group type: EXPERIMENTAL
Intervention: 5M CRT monitor
Number of subjects: 100
Study 17729000 — intervention group
Group type: COMPARATOR
Intervention: 3M LCD monitor
Number of subjects: 100
Study 10942064 — intervention group
Group type: EXPERIMENTAL
Intervention: CMB-401 (dosing commenced at 2 mg/m2 and progressed to 16 mg/m2 over seven cohorts)
Number of subjects: 34
Study 8843892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (15 mg) for 12 months
Number of subjects: 96
Study 8843892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 1387739 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 62
Study 1387739 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 62
Study 6565475 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin
Number of subjects: 36
Study 6565475 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for ten days
Number of subjects: 36
Study 31033900 — intervention group
Group type: COMPARATOR
Intervention: Concentric Resistance Training (CNC RT)
Number of subjects: 90
Study 31033900 — intervention group
Group type: COMPARATOR
Intervention: Eccentric Resistance Training (ECC RT)
Number of subjects: 90
Study 31033900 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait-list, no-exercise control group
Number of subjects: 90
Study 30088607 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent haemostasis with TR Band™ device
Number of subjects: 0
Study 30088607 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemostasis with an elastic adhesive bandage
Number of subjects: 0
Study 27091830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking abstinence intervention (intensity varied by risk group)
Number of subjects: 382
Study 27091830 — intervention group
Group type: COMPARATOR
Intervention: Control group (smoking abstinence booklet plus newsletters about parenting and stress)
Number of subjects: 382
Study 27091830 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study 27091830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 382
Study 25104497 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid blockade using RU38486 (mifepristone) and metyrapone
Number of subjects: 14
Study 25104497 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study 22424008 — intervention group
Group type: EXPERIMENTAL
Intervention: CSS (Clinical Synergy Between PCI With Taxus and Cardiac Surgery score)
Number of subjects: 2094
Study 22424008 — intervention group
Group type: EXPERIMENTAL
Intervention: NERS (New Risk Stratification score)
Number of subjects: 2094
Study 22424008 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery score)
Number of subjects: 2094
Study 22424008 — intervention group
Group type: EXPERIMENTAL
Intervention: CSS and NERS
Number of subjects: 2094
Study 20421752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day spiritual retreat
Number of subjects: 199
Study 20421752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retreat)
Number of subjects: 199
Study 17415205 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 90 Gy with no selective beam channel blocking (Group 1)
Number of subjects: 358
Study 17415205 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 Gy with no selective beam channel blocking (Group 2)
Number of subjects: 358
Study 17415205 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 Gy with selective beam channel blocking (Group 3)
Number of subjects: 358
Study 15625212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate
Number of subjects: 40
Study 15625212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12407605 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AF0144 (2.7 g/kg)
Number of subjects: 36
Study 12407605 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 36
Study 12407605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose AF0144 (1.8 g/kg)
Number of subjects: 36
Study 12407605 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 36
Study 12407605 — intervention group
Group type: EXPERIMENTAL
Intervention: AF0144
Number of subjects: 36
Study 10501521 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary movements of the stimulated hand
Number of subjects: 2
Study 7474322 — intervention group
Group type: EXPERIMENTAL
Intervention: Finapres during rewarming
Number of subjects: 16
Study 7474322 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin-assisted rewarming
Number of subjects: 16
Study 2180749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (short exposure before insemination)
Number of subjects: 57
Study 2180749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (long exposure before insemination)
Number of subjects: 57
Study 2180749 — intervention group
Group type: COMPARATOR
Intervention: Control semen
Number of subjects: 57
Study 31187784 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (defined as BMI for age and gender above +1 and below +2 SD scores)
Number of subjects: 7930
Study 31187784 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (defined as BMI for age and gender above +2 SD scores)
Number of subjects: 7930
Study 31187784 — intervention group
Group type: COMPARATOR
Intervention: Comparison with WHO-based national prevalence rate of obesity reported in 2004
Number of subjects: 7930
Study 31187784 — intervention group
Group type: COMPARATOR
Intervention: Age group comparison (adolescents vs children)
Number of subjects: 7930
Study 31187784 — intervention group
Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 7930
Study 31187784 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of developing gas bloating and vomiting
Number of subjects: 7930
Study 27012728 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (β1-selective adrenergic blockade)
Number of subjects: 11
Study 27012728 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective adrenergic blockade)
Number of subjects: 11
Study 27012728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study 27144828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cells cultured on β‐TCP in combination with rh‐PDGF‐BB
Number of subjects: 14
Study 27144828 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 14
Study 24080653 — intervention group
Group type: EXPERIMENTAL
Intervention: motavizumab‐YTE (0.3, 3, 15, or 30 mg/kg)
Number of subjects: 31
Study 24080653 — intervention group
Group type: COMPARATOR
Intervention: motavizumab
Number of subjects: 31
Study 24080653 — intervention group
Group type: EXPERIMENTAL
Intervention: motavizumab‐YTE
Number of subjects: 31
Study 24080653 — intervention group
Group type: COMPARATOR
Intervention: motavizumab‐YTE and motavizumab
Number of subjects: 31
Study 21747321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine
Number of subjects: 313
Study 21747321 — intervention group
Group type: COMPARATOR
Intervention: Control group (full-term infants)
Number of subjects: 313
Study 20715888 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized working memory training for 5 weeks
Number of subjects: 21
Study 20715888 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 17146738 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 523
Study 17146738 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 lymphadenectomy
Number of subjects: 523
Study 14768922 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% with sufentanil 0.75 microg mL(‐1)
Number of subjects: 450
Study 14768922 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.125% with sufentanil 0.75 microg mL(‐1)
Number of subjects: 450
Study 14768922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.175% with sufentanil
Number of subjects: 450
Study 14768922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% without sufentanil
Number of subjects: 450
Study 12899372 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopaths
Number of subjects: 67
Study 12899372 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychopaths
Number of subjects: 67
Study 9667592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepidermal nerve fiber (IENF) density assessment via punch biopsy
Number of subjects: 32
Study 9667592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural nerve biopsy
Number of subjects: 32
Study 9667592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment of neuropathic pain
Number of subjects: 32
Study 9667592 — intervention group
Group type: EXPERIMENTAL
Intervention: Punch skin biopsy from proximal and distal sites
Number of subjects: 32
Study 8596746 — intervention group
Group type: EXPERIMENTAL
Intervention: Health resort treatment
Number of subjects: 15
Study 2788001 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with naloxone (50 mg)
Number of subjects: 11
Study 2788001 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation with saline (placebo)
Number of subjects: 11
Study 358815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous digoxin
Number of subjects: 9
Study 358815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg intravenous digoxin
Number of subjects: 9
Study 358815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg intravenous digoxin
Number of subjects: 9
Study 31266043 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise group
Number of subjects: 90
Study 31266043 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 90
Study 28494047 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately Loaded Implants (IL)
Number of subjects: 15
Study 28494047 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loaded Nonsubmerged Implants (NS)
Number of subjects: 15
Study 28494047 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loaded Submerged Implants (SI)
Number of subjects: 15
Study 26883612 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25 percent Sodium Hypochlorite (NaOCl)
Number of subjects: 81
Study 26883612 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 81
Study 26883612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Sulfate (FS)
Number of subjects: 81
Study 23849964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg)
Number of subjects: 350
Study 23849964 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 350
Study 23849964 — intervention group
Group type: COMPARATOR
Intervention: Control Group (chronic statin therapy without reloading)
Number of subjects: 350
Study 21729881 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2108622 on 19pter‐p13.11
Number of subjects: 5006
Study 21729881 — intervention group
Group type: EXPERIMENTAL
Intervention: rs11057830 on 12q24.31
Number of subjects: 5006
Study 21729881 — intervention group
Group type: EXPERIMENTAL
Intervention: rs964184 on 11q23.3
Number of subjects: 5006
Study 21729881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined meta-analysis
Number of subjects: 5006
Study 21729881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SNPs
Number of subjects: 5006
Study 21729881 — intervention group
Group type: COMPARATOR
Intervention: GWAS cohort (n= 992)
Number of subjects: 5006
Study 19712448 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised O&M-training in using the identification cane
Number of subjects: 190
Study 19712448 — intervention group
Group type: COMPARATOR
Intervention: Usual care O&M-training
Number of subjects: 190
Study 16448524 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (2 mg/day) plus metformin (1500 mg/day)
Number of subjects: 99
Study 16448524 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) plus metformin (1500 mg/day)
Number of subjects: 99
Study 12632526 — intervention group
Group type: EXPERIMENTAL
Intervention: formula of amino acid enriched BCAA (BCAA group)
Number of subjects: 40
Study 12632526 — intervention group
Group type: COMPARATOR
Intervention: formula of amino acid (AA group)
Number of subjects: 40
Study 10697061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily
Number of subjects: 629
Study 10697061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg twice daily
Number of subjects: 629
Study 10697061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 629
Study 10697061 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oseltamivir recipients
Number of subjects: 629
Study 9333108 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (ED50) in parents
Number of subjects: 44
Study 9333108 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (ED50) in children
Number of subjects: 44
Study 9333108 — intervention group
Group type: EXPERIMENTAL
Intervention: Heritability estimation
Number of subjects: 44
Study 8222517 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose polymer solution (272 +/- 1.1 mosmol/kg)
Number of subjects: 11
Study 8222517 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% glucose polymer solution (277 +/- 2.0 mosmol/kg)
Number of subjects: 11
Study 8222517 — intervention group
Group type: COMPARATOR
Intervention: 1.36% glucose solution (339 +/- 1.9 mosmol/kg)
Number of subjects: 11
Study 8222517 — intervention group
Group type: COMPARATOR
Intervention: 2.27% glucose solution (393 +/- 3.2 mosmol/kg)
Number of subjects: 11
Study 8222517 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose polymer solution (284 +/- 2.0 mosmol/kg)
Number of subjects: 11
Study 8222517 — intervention group
Group type: COMPARATOR
Intervention: 3.86% glucose solution (482 +/- 1.6 mosmol/kg)
Number of subjects: 11
Study 8222517 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% glucose polymer solution with 0.35% glucose
Number of subjects: 11
Study 3774833 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking (placebo or 1.29%, 2.84%, 4.00%)
Number of subjects: 0
Study 30515390 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut water (2L daily for 4 days)
Number of subjects: 8
Study 26167946 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 284
Study 26167946 — intervention group
Group type: EXPERIMENTAL
Intervention: Present-centered therapy
Number of subjects: 284
Study 26167946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociative symptoms
Number of subjects: 284
Study 24388435 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific temporal training (TT, n=11)
Number of subjects: 18
Study 24388435 — intervention group
Group type: COMPARATOR
Intervention: Control non-temporal training (NT, n=7)
Number of subjects: 18
Study 22575312 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital ST
Number of subjects: 3602
Study 22575312 — intervention group
Group type: COMPARATOR
Intervention: Out-of-hospital ST
Number of subjects: 3602
Study 20485707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus xylometazoline (LX)
Number of subjects: 181
Study 20485707 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (L)
Number of subjects: 181
Study 18400028 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic movement of 29 pre-molars for 8 weeks
Number of subjects: 16
Study 18400028 — intervention group
Group type: COMPARATOR
Intervention: Control group of 18 contralateral pre-molars not subjected to orthodontic movement
Number of subjects: 16
Study 18400028 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of periodontal parameters (Plaque Index, Gingival Index, probing depth, bleeding on probing)
Number of subjects: 16
Study 18400028 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of relationship between resorption and periodontal parameters
Number of subjects: 16
Study 16083628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin treatment (group A, n = 18, folic acid 5 mg/d, vitamin B(6) 50 mg/d, B(12) 1000 microg/d)
Number of subjects: 36
Study 16083628 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, n = 18)
Number of subjects: 36
Study 12064916 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (75 mg/kg/day)
Number of subjects: 144
Study 12064916 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (50 mg/kg/day)
Number of subjects: 144
Study 9793811 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 mcg/kg (C5)
Number of subjects: 80
Study 9793811 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 mcg/kg (C2.5)
Number of subjects: 80
Study 9793811 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 100 mcg/kg (D)
Number of subjects: 80
Study 9793811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 80
Study 7543785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine (FM) 100 mg/m2 on days 1 + 8 + 15, followed by maintenance courses (q3w)
Number of subjects: 54
Study 7543785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine (FM)
Number of subjects: 54
Study 2696659 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime
Number of subjects: 296
Study 2696659 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg single dose
Number of subjects: 296
Study 825895 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mug TRH (thyrotropin releasing hormone) by slow, continuous infusion over 4 hours
Number of subjects: 10
Study 825895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28691141 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine (30 mg per day intravenously for 14 consecutive days)
Number of subjects: 60
Study 28691141 — intervention group
Group type: COMPARATOR
Intervention: Standard management alone (controls)
Number of subjects: 60
Study 26810358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interactive multimedia Internet intervention program (UV4.me)
Number of subjects: 0
Study 26810358 — intervention group
Group type: EXPERIMENTAL
Intervention: Website of a skin cancer organization
Number of subjects: 0
Study 26810358 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 0
Study 24677117 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone (300‐mg loading dose, then 75 mg/day for 28 days)
Number of subjects: 0
Study 24677117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus omeprazole 80 mg, esomeprazole 40 mg or lansoprazole 60 mg
Number of subjects: 0
Study 24677117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus esomeprazole 20 mg/low‐dose acetylsalicylic acid (ASA) 81 mg
Number of subjects: 0
Study 24677117 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone (75 mg/day for 9 days)
Number of subjects: 0